Clinical Edge Journal Scan

Perimenstrual migraine attacks are exclusively migraine attacks without aura, recommends study


 

Key clinical point: The perimenstrual period was associated with an increased susceptibility to migraine without aura exclusively in both women who experienced migraine with and without aura; hence, the study recommended that only attacks without aura should be considered for a perimenstrual migraine diagnosis.

Major finding: A significant interaction was observed between the perimenstrual window and migraine subtype for migraine attack occurrence ( P = .022), with the effect of the perimenstrual window being greater among women with migraine without aura (odds ratio [OR] 1.57; 95% CI 1.45-1.69) vs with aura (OR 1.36; 95% CI 1.24-1.49). Women with migraine with vs without aura showed similar increase in migraine attacks without aura during the perimenstrual window ( P = .224).

Study details: This longitudinal electronic diary study included 526 premenopausal women diagnosed with migraine with or without aura.

Disclosures: This study was supported by ZonMw and the Dutch Brain Foundation. Five authors, including the lead author, declared receiving independent support from the study funders. Some authors declared receiving consultancy and independent support from various sources.

Source: Verhagen IE et al. Migraine with and without aura in relation to the menstrual cycle and other hormonal milestones: A prospective cohort study. Cephalalgia. 2023;43(6) (May 31). doi: 10.1177/03331024231164322

Recommended Reading

Update on Migraine Prevention 2023
Migraine ICYMI
COVID-19 history worsens clinical course of migraine
Migraine ICYMI
Migraine raises severity of vasomotor symptoms in midlife women
Migraine ICYMI
Meta-analysis elucidates bidirectional association between psoriasis and migraine
Migraine ICYMI
Maternal migraine raises risk for childhood cancers in offspring
Migraine ICYMI
Omega-3 supplementation may improve inflammatory markers in episodic migraine
Migraine ICYMI
Commentary: CGRP medications, COVID-19, and menopause in patients with migraine, June 2023
Migraine ICYMI
New diagnostic criteria for menstrual migraine
Migraine ICYMI
Concomitant oral preventive treatment may dampen response in chronic migraine treated with onabotulinumtoxinA
Migraine ICYMI
Efficacy of galcanezumab after 1 week of treatment for migraine predicts responders at 3 months
Migraine ICYMI